annb0t
Top 20
Mesoblast Limited MESO announced that it has partnered with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to develop a pivotal phase III study of MESOâs lead product candidate, Ryoncil (remestemcel-L), to treat adults with steroid-refractory acute graft versus host disease (SR-aGvHD).
The BMT CTN is a body formed with a conglomeration of centers that collectively conduct approximately 80% of all the U.S. allogeneic blood and marrow transplants. The BMT CTN is funded ...
>>> Read more: Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
The BMT CTN is a body formed with a conglomeration of centers that collectively conduct approximately 80% of all the U.S. allogeneic blood and marrow transplants. The BMT CTN is funded ...
>>> Read more: Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
